Delta-Fly Pharma Company Description

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer.

The company was incorporated in 2010 and is headquartered in Tokushima, Japan.

Delta-Fly Pharma, Inc.

Country	Japan
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	13
CEO	Kiyoshi Eshima

Contact Details

Address: 37-5 Nishikino Tokushima, 771-0116 Japan
Website	delta-flypharma.co.jp

Stock Details

Ticker Symbol	4598
Exchange	Tokyo Stock Exchange
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3549370009
SIC Code	2836

Key Executives

Name	Position
Kiyoshi Eshima	Chief Executive Officer